Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for three months ended June 30, 2026, released August 10, 2026.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for three months ended June 30, 2026, released August 10, 2026
- Operational update included alongside financial results
- Full financial details and management commentary available in Exhibit 99.1
Item 8.01 · Other Events
- Updated corporate presentation posted August 10, 2026
- Exhibit 99.2 contains the presentation and may outline updated pipeline, strategy, or milestones
- Investor relevance depends on presentation-specific disclosures, including potential clinical or commercial updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 net product revenue $218.4M, up 46% YoY, led by AUVELITY sales of $180.3M, up 51%
- Alzheimer’s agitation launch expands AUVELITY’s market; age 65+ new-to-brand prescriptions rose 126% in eight weeks
- Commercial investment increased SG&A to $208.1M from $130.3M, leaving net loss $51.3M and cash $319.9M
- SYMBRAVO sales reached $2.3M, up 461%, while expanded sales force of approximately 150 representatives broadens market access
- AXS-12 NDA accepted with May 1, 2027 PDUFA date; solriamfetol ADHD Phase 3 trials initiated for children and adolescents
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.